Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
CMS Proposed Rule Comment Form, 60 Days
CMS has published a comment form on regulations.gov for proposed rule CMS-2026-1256-0001, opening a 60-day public comment period. The form allows individuals and organizations to submit feedback on the proposed rule. The actual subject matter and regulatory requirements of the underlying proposed rule are not detailed in this comment form document.
Ion Pair Liquid Crystal Formulations for Long-Acting Injectables of Poorly Soluble Drugs
USPTO published patent application US20260097044A1 by FORDOZ PHARMA Corp. disclosing ion pair liquid crystal formulations designed to solubilize poorly soluble drugs and enable controlled release via parenteral administration. The application covers ion pairs including Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine incorporated into liquid crystal vehicles.
Cannabinoid Analogs Cancer Treatment Patent Application
USPTO published patent application US20260097049A1 by BlackStone Therapeutics LLC covering hexahydrocannabinol (HHC), hexahydrocannabidivarin (H4CBDV), and hexahydrocannabidivarin (H4CBDV) derivatives for cancer treatment and prevention. The application includes pharmaceutical compositions and methods of use for pancreatic and lung cancers.
ModernaTX Betacoronavirus mRNA Vaccine Lipid Nanoparticle Patent Application
USPTO published patent application US20260097110A1 by ModernaTX, Inc. for betacoronavirus mRNA vaccines formulated in lipid nanoparticles. The application covers RNA vaccines, combination vaccines, and methods of using the vaccines and compositions. The filing was submitted December 5, 2025, with inventors Giuseppe Ciarametta and Sunny Himansu.
Small Molecule NVL2 Inhibitors, Dibenzothiazepinone and Dibenzazepinone Compounds for Cancer Treatment
The USPTO published patent application US20260097047A1 assigned to the Board of Regents, The University of Texas System, covering dibenzothiazepinone and dibenzazepinone-based small molecule inhibitors targeting the ribosome biogenesis factor NVL2 for cancer treatment. The application includes methods for treating cancers, pharmaceutical compositions, and screening methods for candidate therapeutics.
Helperby Therapeutics Antimicrobial Combination Patent - Three Agents
USPTO published Helperby Therapeutics' patent application for antimicrobial combination therapy comprising three distinct antimicrobial agents. The invention covers combinations including ceftazidime, polymyxins, zidovudine, doxycycline, fosfomycin, levofloxacin, meropenem, rifampicin, and gentamicin for treating bacterial infections. This application was filed September 20, 2023.
Large-Scale Liposomal Aminoglycoside Manufacturing Method
USPTO published patent application US20260096989A1 by Insmed Incorporated for large-scale manufacturing of liposomal aminoglycoside drug formulations. The method uses a specific lipid-to-drug stream flow rate ratio to achieve high encapsulation efficiency with a lipid-to-drug weight ratio below 1:1.
Cardiac Myosin Inhibitor Aficamten for Hypertrophic Cardiomyopathy
Cardiac Myosin Inhibitor Aficamten for Hypertrophic Cardiomyopathy
Conditions of Coverage for Portable X-ray Suppliers, Reinstatement of Information Collection, Comments Due June 9, 2026
CMS published a 60-day PRA notice seeking public comment on reinstating an existing information collection regarding Conditions of Coverage for Portable X-ray Suppliers. The collection covers portable X-ray services performed in Skilled Nursing Facilities and Long-term Care settings under Medicare/Medicaid. Comments must be received by June 9, 2026.
Self-Attestation Form for Provider Recertification Under PRA
CMS published a 60-day Paperwork Reduction Act notice announcing a new Self-Attestation for Recertification form for Comprehensive Outpatient Rehabilitation Facilities (CORFs), Outpatient Physical Therapy/Speech Language Pathology (OPT/SLP), and Rural Health Clinics (RHCs) Providers and PXR Suppliers. The notice invites public comment on burden estimates and information collection aspects through June 9, 2026.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
722 changes in last 7 days
Latest high priority updates
141 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.